Investigation of Predictive Biomarkers in Patients With Advanced BTC Treated With Lenvatinib Plus Pembrolizumab
CHA University
CHA University
City of Hope Medical Center
National Institutes of Health Clinical Center (CC)
University Hospital, Angers
Ohio State University
Hoosier Cancer Research Network
West China Hospital
Yale University
Mayo Clinic
National Institutes of Health Clinical Center (CC)
University of California, Irvine
Jazz Pharmaceuticals
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Servier
Arvinas Inc.
Case Comprehensive Cancer Center
Myeloid Therapeutics
Mayo Clinic
Mayo Clinic
Stanford University
National Institutes of Health Clinical Center (CC)
University of Kentucky
Oslo University Hospital
DualityBio Inc.
Bold Therapeutics, Inc.
Big Ten Cancer Research Consortium
J-Pharma Co., Ltd.
Genfit
Zhejiang University
National Institutes of Health Clinical Center (CC)
Massachusetts General Hospital
Aichi Medical University
Tata Memorial Centre
Apollo Therapeutics Ltd
Taiho Oncology, Inc.
Alentis Therapeutics AG
Shanghai Zhongshan Hospital
West China Hospital
University Hospital, Bordeaux
Mayo Clinic
University of Maryland, Baltimore
Nantes University Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Memorial Sloan Kettering Cancer Center
West China Hospital
UNICANCER
Tango Therapeutics, Inc.
National Institutes of Health Clinical Center (CC)